Mammary cancer promotion by ovarian hormones involves IGFR/AKT/mTOR signaling

Steroids

Volumn 77, Issue 7, 2012, Pages 791-797

  Arumugam, Arunkumar ^a   Parada, Jacqueline ^a   Rajkumar, Lakshmanaswamy ^a  

^a Paul L Foster School of Medicine   (United States)

Author keywords

Estrogen; IGFR; Mammary lesions; Mammary tumor; mTOR; Progesterone

Indexed keywords

ESTRADIOL; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INSULIN GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METHYLNITROSOUREA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROGESTERONE; PROTEIN KINASE B; PROTEIN SHC; PROTEIN SHC1; SOMATOMEDIN; SOS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HORMONAL THERAPY; IMMUNOBLOTTING; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CARCINOGENS; DNA PRIMERS; ESTRADIOL; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; OVARY; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SOMATOMEDIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

RATTUS;

EID: 84861203286     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.03.009     Document Type: Article

References (43)

1. M.C. Pike, D.V. Spicer, L. Dahmoush, and M.F. Press Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk Epidemiol Rev 15 1993 17 35 (Pubitemid 23269068)
2. S.S. Coughlin, and D.U. Ekwueme Breast cancer as a global health concern Cancer Epidemiol 33 2009 315 318
3. K. McPherson, C.M. Steel, and J.M. Dixon ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics BMJ 321 2000 624 628
4. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 2002 321 333 (Pubitemid 34761611)
5. L.J. Hofseth, A.M. Raafat, J.R. Osuch, D.R. Pathak, C.A. Slomski, and S.Z. Haslam Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J Clin Endocrinol Metab 84 1999 4559 4565
6. P.M. Ravdin Hormone replacement therapy and the increase in the incidence of invasive lobular cancer Breast Dis 30 2009 3 8
7. J.T. Isaacs Genetic control of resistance to chemically induced mammary adenocarcinogenesis in the rat Cancer Res 46 1986 3958 3963 (Pubitemid 16075891)
8. L.A. Shepel, and M.N. Gould The genetic components of susceptibility to breast cancer in the rat Prog Exp Tumor Res 35 1999 158 169
9. H.J. Thompson, and M. Singh Rat models of premalignant breast disease J Mammary Gland Biol Neoplasia 5 2000 409 420 (Pubitemid 32236771)
10. S.J. Lu, and M.C. Archer Ha-ras oncogene activation in mammary glands of N-methyl-N-nitrosourea-treated rats genetically resistant to mammary adenocarcinogenesis Proc Natl Acad Sci USA 89 1992 1001 1005
11. J.E. Korkola, and M.C. Archer Resistance to mammary tumorigenesis in Copenhagen rats is associated with the loss of preneoplastic lesions Carcinogenesis 20 1999 221 227 (Pubitemid 29057553)
12. M.N. Gould, and R. Zhang Genetic regulation of mammary carcinogenesis in the rat by susceptibility and suppressor genes Environ Health Perspect 93 1991 161 167
13. L.A. Shepel, H. Lan, J.D. Haag, G.M. Brasic, M.E. Gheen, and J.S. Simon Genetic identification of multiple loci that control breast cancer susceptibility in the rat Genetics 149 1998 289 299 (Pubitemid 28246804)
14. L. Rajkumar, A. Arumugam, A. Elsayed, S. Schecter, E. Kotkowski, and R. Castillo Long-term hormonal promotion overcomes genetic resistance to mammary cancer Steroids 76 2010 31 37
15. L. Rajkumar, A. Canada, D. Esparza, K. Collins, E. Moreno, and H. Duong Decreasing hormonal promotion is key to breast cancer prevention Endocrine 35 2009 220 226
16. D. Sachdev, and D. Yee The IGF system and breast cancer Endocr Relat Cancer 8 2001 197 209 (Pubitemid 32947642)
17. C. Laban, S.A. Bustin, and P.J. Jenkins The GH-IGF-I axis and breast cancer Trends Endocrinol Metab 14 2003 28 34 (Pubitemid 36733929)
18. W. Imagawa, V.K. Pedchenko, J. Helber, and H. Zhang Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis J Steroid Biochem Mol Biol 80 2002 213 230 (Pubitemid 34233741)
19. D.L. Kleinberg, M. Feldman, and W. Ruan IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis J Mammary Gland Biol Neoplasia 5 2000 7 17
20. W. Ruan, and D.L. Kleinberg Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development Endocrinology 140 1999 5075 5081
21. M. Lanzino, C. Morelli, C. Garofalo, M.L. Panno, L. Mauro, and S. Ando Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer Curr Cancer Drug Targets 8 2008 597 610
22. E.M. Fox, J. Andrade, and M.A. Shupnik Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways Steroids 74 2009 622 627
23. P.V. Elizalde, C. Lanari, A.A. Molinolo, F.K. Guerra, M.E. Balana, and M. Simian Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas J Steroid Biochem Mol Biol 67 1998 305 317 (Pubitemid 28559228)
24. M.E. Balana, L. Labriola, M. Salatino, F. Movsichoff, G. Peters, and E.H. Charreau Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells Oncogene 20 2001 34 47 (Pubitemid 32142336)
25. R.P. Carnevale, C.J. Proietti, M. Salatino, A. Urtreger, G. Peluffo, and D.P. Edwards Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways Mol Endocrinol 21 2007 1335 1358 (Pubitemid 46984741)
26. S.M. Alam, M. Rajendran, S. Ouyang, S. Veeramani, L. Zhang, and M.F. Lin A novel role of Shc adaptor proteins in steroid hormone-regulated cancers Endocr Relat Cancer 16 2009 1 16
27. P.G. Dharmawardana, B. Peruzzi, A. Giubellino, T.R. Burke Jr, and D.P. Bottaro Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy Anticancer Drugs 17 2006 13 20
28. E. Surmacz Function of the IGF-I receptor in breast cancer J Mammary Gland Biol Neoplasia 5 2000 95 105
29. K.S. Ravichandran Signaling via Shc family adapter proteins Oncogene 20 2001 6322 6330 (Pubitemid 32977841)
30. J. Wang, I. Kuiatse, A.V. Lee, J. Pan, A. Giuliano, and X. Cui Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation Mol Cancer Res 8 2010 266 277
31. M. Salatino, R. Schillaci, C.J. Proietti, R. Carnevale, I. Frahm, and A.A. Molinolo Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity Oncogene 23 2004 5161 5174 (Pubitemid 38980349)
32. D. Morgensztern, and H.L. McLeod PI3K/Akt/mTOR pathway as a target for cancer therapy Anticancer Drugs 16 2005 797 803 (Pubitemid 41215743)
33. E. Jacinto, and A. Lorberg TOR regulation of AGC kinases in yeast and mammals Biochem J 410 2008 19 37 (Pubitemid 351300322)
34. A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, and D.B. Evans Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 2005 5319 5328 (Pubitemid 41003721)
35. Z. Liu, P. Hou, M. Ji, H. Guan, K. Studeman, and K. Jensen Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers J Clin Endocrinol Metab 93 2008 3106 3116
36. L. Simi, N. Pratesi, M. Vignoli, R. Sestini, F. Cianchi, and R. Valanzano High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer Am J Clin Pathol 130 2008 247 253
37. H. Tsao, V. Goel, H. Wu, G. Yang, and F.G. Haluska Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma J Invest Dermatol 122 2004 337 341 (Pubitemid 38281053)
38. Q.B. She, E. Halilovic, Q. Ye, W. Zhen, S. Shirasawa, and T. Sasazuki 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors Cancer Cell 18 2010 39 51
39. Y. Mamane, E. Petroulakis, L. Rong, K. Yoshida, L.W. Ler, and N. Sonenberg eIF4E - from translation to transformation Oncogene 23 2004 3172 3179 (Pubitemid 38638828)
40. V.A. Polunovsky, and P.B. Bitterman The cap-dependent translation apparatus integrates and amplifies cancer pathways RNA Biol 3 2006 10 17
41. G. Armengol, F. Rojo, J. Castellvi, C. Iglesias, M. Cuatrecasas, and B. Pons 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications Cancer Res 67 2007 7551 7555 (Pubitemid 47281345)
42. C. Teixeira, J.C. Reed, and M.A. Pratt Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells Cancer Res 55 1995 3902 3907
43. Y. Huang, S. Ray, J.C. Reed, A.M. Ibrado, C. Tang, and A. Nawabi Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells Breast Cancer Res Treat 42 1997 73 81 (Pubitemid 27056730)